Aerosolized surfactants

Current Opinion in Pediatrics

Volumn 19, Issue 2, 2007, Pages 155-162

  Mazela, Jan ^a   Merritt, T Allen ^b   Finer, Neil N ^c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Aerosol; Infant; Respiratory distress syndrome; Surfactant

Indexed keywords

BERACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; PORACTANT; SURFACTANT;

APNEA; BLOOD PRESSURE; BRADYCARDIA; BRAIN BLOOD FLOW; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; ENDOTRACHEAL INTUBATION; FATTY ACID DESATURATION; HUMAN; HYPERCAPNIA; HYPOXIA; LUNG DYSPLASIA; NEBULIZATION; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; NOSE IRRITATION; PALLOR; PARTICLE SIZE; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; REVIEW; SIDE EFFECT; SKIN IRRITATION; STOMACH DISTENSION; TRACHEA OBSTRUCTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; CONTINUOUS POSITIVE AIRWAY PRESSURE; HUMANS; INFANT, NEWBORN; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 34247555845     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32807fb013     Document Type: Review

References (66)

1. Soll R, Morley C. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001; (2):CD000510.
2. Soll R. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000; (2): CD000511.
3. Mazela J, Merritt T, Gadzinowski J, Sinha S. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases. Acta Paediatr 2006; 95:1036-1048. Paper presents the history of surfactant therapy and potential promises for treating respiratory failure with novel synthetic surfactants in development.
4. van der Bleek J, Plotz F, van Overbeek F, et al. Distribution of exogenous surfactant in rabbits with severe respiratory failure: the effect of volume. Pediatr Res 1993; 34:154-158.
5. Merritt T, Kheiter A, Cochrane C. Positive end-expiratory pressure during KL4 surfactant instillation enhances intrapulmonary distribution in a simian model of respiratory distress syndrome. Pediatr Res 1995; 38:211-217.
6. Thomson M. Continuous positive airway pressure and surfactant; combined data from animal experiments and clinical trials. Biol Neonate 2002; 81 (Suppl 1): 16-19.
7. Hilgendorff A, Reiss I, Ruppert C, et al. Positive end-expiratory pressure modifies response to recombinant and natural exogenous surfactant in ventilated immature newborn rabbits. Biol Neonate 2006; 90:210-216.
8. Cowan F, Whitelaw A, Silverman M. Cerebral blood flow velocity changes after rapid administration of surfactant. Arch Dis Child 1991; 66:1105-1109.
9. Murdoch E, Kempley S. Randomized trial examining cerebral haemodynamics following artificial or animal surfactant. Acta Paediatr 1998; 87:411-415.
10. Hascoet J, Andre M, Didier F, et al. Cebral hemodynamic and EEG effects of treatment with natural versus synthetic surfactant. Pediatr Res 1995; 37:211A.
11. Kaiser J, Gauss C, Williams D. Surfactant administration acutely affects cerebral and systemic hemodynamics and gas exchange in very-low-birthweight infants. J Pediatr 2004; 144:809-814.
12. Raju T, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis. J Pediatr 1993; 123:603-610.
13. Sinha S, Lacaze-Masmonteil T, Valls i Soler A, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115:1030-1038.
14. Moya F, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005; 115:1018-1029.
15. Bloom B, Kattwinkel J, Hall R, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997; 100:31-38.
16. Marshall T, Deeder R, Pai S, et al. Physiologic changes associated with endotracheal intubation in preterm infants. Crit Care Med 1984; 12:501-503.
17. Kelly M, Finer N. Nasotracheal intubation in the neonate: physiologic responses and effects of atropine and pancuronium. J Pediatr 1984; 105:303-309.
18. Newman B, Oh K. Iatrogenic tracheobronchial perforation in infants. J Thorac Imaging 1994; 9:269-272.
19. Leone T, Rich W, Finer N. Neonatal intubation: success of pediatric trainees. J Pediatr 2005; 146:638-641.
20. Horbar J, Carpenter J, Buzas J, et al. Timing of initial surfactant treatment for infants 23 to 29 weeks gestation: is routine practice evidence based? Pediatrics 2004; 113:1593-1602.
21. Vermont Oxford Network. Expanded database summary. 2003.
22. Vermont Oxford Network. Expanded database summary. 2005.
23. Yost C, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2000; (2):CD001456.
24. Yost C, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome (Cochrane Review). In: The Cochrane Library 2002; Issue 2. Oxford: Update Software.
25. Kattwinkel J, Robinson M, Bloom B, et al. Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J Perinatol 2004; 24:360-365.
26. Trevisanuto D, Grazzina N, Ferrarese P, et al. Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome. Biol Neonate 2005; 87:217-220.
27. Gregory G, Kitterman J, Phibbs R, et al. Treatment of the idiopathic respiratory-distress syndrome with continuous positive airway pressure. N Engl J Med 1971; 284:1333-1340.
28. Verder H, Robertson B, Greisen G, et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group. N Engl J Med 1994; 331:1051-1055.
29. Avery M, Tooley W, Keller J, et al. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 1987; 79:26-30.
30. Van Marter L, Allred E, Pagano M, et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics 2000; 105:1194-1201.
31. Richardson C, Jung A. Effect of continuous positive airway pressure on pulmonary function and blood gases of infants with respiratory distress syndrome. Pediatr Res 1978; 12:771-774.
32. Gaon P, Lee S, Hannan S, et al. Assessment of effect of nasal continuous positive pressure on laryngeal opening using fibre optic laryngoscopy. Arch Dis Child Fetal Neonatal Ed 1999; 80:F230-F232.
33. Thomson M, Yoder B, Winter V, et al. Treatment of immature baboons for 28 days with early nasal continuous positive airway pressure. Am J Respir Crit Care Med 2004; 169:1054-1062.
34. Jobe A, Kramer B, Moss T, et al. Decreased indicators of lung injury with continuous positive expiratory pressure in preterm lambs. Pediatr Res 2002; 52:387-391.
35. Mulrooney N, Champion Z, Moss T, et al. Surfactant and Physiological Responses of Preterm Lambs to Continuous Positive Airway Pressure. Am J Respir Crit Care Med 2004; 171:488-493.
36. Loeliger M, Inder T, Cain S, et al. Cerebral outcomes in a preterm baboon model of early versus delayed nasal continuous positive airway pressure. Pediatrics 2006; 118:1640-1653. Study focused on early and delayed CPAP therapy in RDS animal model showing more neurological complications linked to delayed CPAP therapy.
37. Narendran V, Donovan E, Hoath S, et al. Early bubble CPAP and outcomes in ELBW preterm infants. J Perinatol 2003; 23:195-199.
38. De Klerk A, De Klerk R. Nasal continuous positive airway pressure and outcomes of preterm infants. J Paediatr Child Health 2001; 37:161-167.
39. Verder H, Albertsen P, Ebbesen F, et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. Pediatrics 1999; 103:E24.
40. Dani C, Bertini G, Pezzati M, et al. Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks' gestation. Pediatrics 2004; 113:E560-E563.
41. Reininger A, Khalak R, Kendig J, et al. Surfactant administration by transient intubation in infants 29 to 35 weeks' gestation with respiratory distress syndrome decreases the likelihood of later mechanical ventilation: a randomized controlled trial. J Perinatol 2005; 25:703-708.
42. Stevens T, Blennow M, Soll R. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2004; (3):CD003063.
43. Booth C, Premkumar M, Yannoulis A, et al. Sustainable use of continuous positive airway pressure in extremely preterm infants during the first week after delivery. Arch Dis Child Fetal Neonatal Ed 2006; 91:F398-F402. Retrospective review of infants less than or equal to 27 weeks initially intubated, given 120 mg of poractant alfa, and thereafter placed on CPAP. This review found that 66% of infants extubated within 24 h could be maintained on CPAP alone, whilst approximately 80% of infants extubated on day 2 could be maintained on CPAP without requiring reintubation.
44. Finer N. To intubate or not: that is the question: continuous positive airway pressure versus surfactant and extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2006; 91:F392-F394. This editorial focuses on recent results of prospective and retrospective studies on early CPAP for neonatal RDS. Based on this review the author concludes that for preterm infants below 26 weeks of gestation early surfactant treatment followed by nCPAP or nasal synchronous intermittent ventilation within the next 24-48 h can be beneficial.
45. Marks L, Notter R, Oberdorster G, McBride J. Ultrasonic jet aerosolization of phospholipids and the effects on surface activity. Pediatr Res 1983; 17:742-747.
46. Dijk P, Heikamp A, Bambang OS. Surfactant nebulisation prevents the adverse effects of surfactant therapy on blood pressure and cerebral blood flow in rabbits with severe respiratory failure. Intensive Care Med 1997; 23:1077-1081.
47. Lewis J, Tabor B, Ikegami M, et al. Lung function and surfactant distribution in saline-lavaged sheep given instilled vs. nebulized surfactant. J Appl Physiol 1993; 74:1256-1264.
48. Lewis JF, Ikegami M, Jobe AH, Absolom D. Physiologic responses and distribution of aerosolized surfactant (Survanta) in a nonuniform pattern of lung injury. Am Rev Respir Dis 1993; 147:1364-1370.
49. Lewis JF, Ikegami M, Jobe AH, Tabor B. Aerosolized surfactant treatment of preterm lambs. J Appl Physiol 1991; 70:869-876.
50. Lewis J, McCaig L. Aerosolized versus instilled exogenous surfactant in a nonuniform pattern of lung injury. Am Rev Respir Dis 1993; 148:1187-1193.
51. Ellyett KM, Broadbent SR, Fawcett ER, Campbell AJ. Surfactant aerosols treatment of respiratory distress syndrome in the spontaneously breathing premature rabbit. Pediatr Res 1996; 39:953-957.
52. Jorch G, Hartl H, Roth B, et al. To the Editor: Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr Pulmonol 1997; 24:222-224.
53. Arroe M, Pedersen-Bjergaard L, Albertsen P, et al. Inhalation of aerosolized surfactant (Exosurf®) to neonates treated with nasal continuous positive airway pressure. Prenat Neonat Med 1998; 3:346-352.
54. Berggren E, Liljedahl M, Winbladh B, et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr 2000; 89:460-464.
55. Hudak M, Martin D, Egan E, et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 1997; 100:39-50.
56. Finer N, Merritt T, Bernstein G, et al. A multicenter pilot study of Aerosurf delivered via nasal continuous positive airway pressure (nCPAP) to prevent respiratory distress syndrome in preterm neonates. Pediatr Res 2006; 59:PAS2006:4840.138. Study showed feasibility of aerosolized lucinactant for RDS treatment. The majority of patients required only one dose of treatment and the typical complications of surfactant liquid instillation were not observed.
57. Johnson M, Mazela J, Pearson R, et al. KL4- surfactant (Aerosurf) retains surface activity after aerosolization. Oral presentation at 8th European Conference on Pediatric and Neonatal Ventilation; 29 March - 1 April 2006; Montroux.
58. Jacobs H, Jobe A, Ikegami M, Jones S. Surfactant phosphatidylcholine source, fluxes, and turnover times in 3-day-old, 10-day-old, and adult rabbits. J Biol Chem 1982; 257:1805-1810.
59. Glatz T, Ikegami M, Jobe A. Metabolism of exogenously administered natural surfactant in the newborn lamb. Pediatr Res 1982; 16:711-715.
60. Stocks J, Hislop A. Structure and function of the respiratory system. Developmental aspects and their relevance to aerosol therapy. In: Bisgaard H, O'Callaghan C, Smaldone G, editors. Drug delivery to the lung. New York: Marcel Dekker; 2002. pp. 47-104.
61. Dolovich M. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care 2000; 45:597-608.
62. Cole C. Special problems in aerosol delivery: neonatal and pediatric considerations. Respir Care 2000; 45:646-651.
63. Becquemin M, Swift D, Bouchikhi A, et al. Particle deposition and resistance in the nose of adults and children. Eur Respir J 1991; 4:694-702.
64. Salmon B, Wilson N, Silverman M. How much aerosol reaches the lungs of wheezy infants and toddlers. Arch Dis Child 1989; 65:401-403.
65. Minocchieri S, Bachmann M, Burren J, et al. In vitro determination of the optimal aerosol particle size for inhalation therapy in preterm infants. Z Geburtshilfe Neonatol 2006; 210:946156.
66. Wagner M, Amthauer H, Sonntag J, et al. Endotracheal surfactant atomization: an alternative to bolus instillation? Crit Care Med 2000; 28:2540-2544.